Fexofenadine Hcl 180Mg Tab for Kidney Stones

"Affirmative. Clinicaltrials.gov information confirms the ongoing recruitment of 78 patients from 1 medical centre, which was first posted on June 29th 2021 and updated most recently on July 16th 2021."

"Presently, there are 5 clinical trials operating with Fexofenadine Hcl 180Mg Tab. Two of these studies have advanced to the third stage and 17 medical sites scattered over San Francisco, California are participating in them."

"Indeed, clinicaltrials.gov is showing that this trial launched on June 29th 2021 and has recently been updated. 78 participants are needed to be enrolled from one site only."

"The primary evaluation metric of this trial is the alteration in USSQ body pain score, which will be assessed on three occasions: pre-surgery (baseline), one or two weeks post-operation and four to six weeks after stent removal. Secondary assessments include adverse drug reactions, duration of NSAID utilization, and quantity of narcotic consumption - all self-reported by patients."

"The eligibility criteria for this clinical trial mandates that participants possess kidney stones and be between the ages of 18-80. A total of 78 patients are required to establish a valid sample size."

"The age-span for participation in this clinical trial is 18 to 80 years old. There are 7 studies available for participants under 18 and 80 studies accessible to individuals over 65."

"Taking into account the Phase 2 trial data, our team estimated Fexofenadine Hcl 180Mg Tab's safety at a moderate score of 2. This drug has some evidence backing its security profile but no efficacy studies to draw from."